Study guide
11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
Certified Pediatric Hematology Oncology Nurse CPHON®
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Testing Logistics 1.3 Test Content Outline and Study Strategy
2 Care Continuum
2.1 Transition of Care: Primary Care and Levels of Care 2.2 End-of-Life Care 2.3 Health Promotion and Maintenance 2.4 Survivorship
3 Leukemias and Lymphomas
3.1 Acute Lymphoblastic Leukemia 3.2 Acute Myeloid Leukemia and Related Myeloid Disease 3.3 Hodgkin and Non-Hodgkin Lymphomas
4 CNS, Neuroblastoma, and Renal Tumors
4.1 Central Nervous System Tumors 4.2 Neuroblastoma 4.3 Wilms Tumor and Other Renal Tumors
5 Sarcomas and Other Solid Tumors
5.1 Osteosarcoma and Ewing Sarcoma 5.2 Rhabdomyosarcoma and Soft-Tissue Sarcomas 5.3 Retinoblastoma, Hepatoblastoma, and Germ Cell Tumors
6 Hematologic Disorders
6.1 Sickle Cell Disease 6.2 Thalassemia and Other Hemoglobinopathies 6.3 Hemophilia, von Willebrand Disease, and Coagulopathies 6.4 Immune Thrombocytopenia, Aplastic Anemia, and Bone Marrow Failure
7 Pathophysiology, Genetics, and Diagnostics
7.1 Anatomy, Physiology, and Pathophysiology Foundations 7.2 Genetics and Genomics 7.3 Diagnostic Testing, Staging, and Prognosis
8 Clinical Trials and Professional Performance
8.1 Clinical Trials and Informed Consent 8.2 Scope, Standards, and Regulatory Practice 8.3 Ethics and Patient-Family Education
9 Chemotherapy and Biotherapy
9.1 Chemotherapy Principles, Classes, and Pediatric Protocols 9.2 Safe Handling, Administration, and Vesicant Precautions 9.3 Biotherapy
10 Immunotherapy, Cellular Therapy, and Radiation
10.1 Immunotherapy 10.2 Cellular Therapies including CAR-T 10.3 Radiation Therapy, I-131-MIBG, and Proton Beam
11 HSCT, Surgery, Transfusion, and Coagulation Therapy
11.1 Hematopoietic Stem Cell Transplantation 11.2 Surgical Management 11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
12 Neurologic, Respiratory, and Cardiovascular Effects
12.1 Neurological Acute, Chronic, and Late Effects 12.2 Respiratory and Lymphatic Effects 12.3 Cardiovascular Effects
13 Gastrointestinal, Renal, Musculoskeletal, and Integumentary Effects
13.1 Gastrointestinal Effects 13.2 Renal and Genitourinary Effects 13.3 Musculoskeletal and Integumentary Effects
14 Endocrine, Hematologic, Immunologic, and Sensory Effects
14.1 Endocrine and Reproductive Effects 14.2 Hematological and Immunological Effects 14.3 Ophthalmological and Otological Effects
15 Pain, Sleep, Fatigue, and Mental Health
15.1 Pain Assessment and Management 15.2 Sleep Disturbance and Fatigue 15.3 Mental Health Effects
16 Supportive Care
16.1 Medical Devices: Venous Access, Pumps, Shunts, and Tubes 16.2 Blood Product Administration 16.3 Colony-Stimulating Factors 16.4 Interdisciplinary, Palliative, and Complementary Care
17 Infectious and Gastrointestinal Emergencies
17.1 Sepsis 17.2 Typhlitis 17.3 Pancreatitis and Bowel Obstruction
18 Metabolic Emergencies
18.1 Diabetes Insipidus and SIADH 18.2 Tumor Lysis Syndrome 18.3 Cytokine Release Syndrome
19 DIC, Hyperleukocytosis, and Sinusoidal Obstructive Syndrome
19.1 Disseminated Intravascular Coagulation and Hemorrhage 19.2 Hyperleukocytosis 19.3 Sinusoidal Obstructive Syndrome (Veno-Occlusive Disease)
20 Sickle Cell and Hemostasis Emergencies
20.1 Splenic Sequestration 20.2 Vaso-Occlusive Crisis 20.3 Stroke, Thrombosis, and Joint Bleed
21 Cardiopulmonary Emergencies
21.1 Acute Chest Syndrome 21.2 Respiratory Distress and Mediastinal Mass 21.3 Pleural Effusions and Arrhythmias
22 Neurologic and Infusion Emergencies
22.1 Increased Intracranial Pressure 22.2 Seizures and PRES 22.3 Spinal Cord Compression 22.4 Hypersensitivity Reactions and Extravasation
23 Family, Caregivers, and Social Integration
23.1 Effects of Acute and Chronic Illness on Patient and Family 23.2 Patient and Family/Caregiver Support 23.3 Integration into Family, School, Work, Camp, and Social Environment
24 Development, Grief, Culture, and Community Resources
24.1 Principles of Growth and Development 24.2 Grief and Bereavement 24.3 Culture, Sexuality and Gender, Socioeconomics, and Community Resources
11.3 Blood Product Therapy, Leukapheresis, and Coagulation Therapy
Key Takeaways Explain This Topic AI
Immunocompromised children need irradiated cellular products to prevent TA-GVHD, plus leukoreduced and CMV-safe units per blood-bank policy.
Platelets treat bleeding or cover a procedure; red cells treat symptomatic anemia. Thresholds are protocol-specific—do not invent a universal 7 g/dL as ONCC fact.
HLA-matched or crossmatched platelets are used for immune refractoriness. Stop the transfusion for suspected allergic, febrile, hemolytic, TRALI, or TACO reactions.
Leukapheresis is used for selected hyperleukocytosis (emergency chapter owns the crisis) and for CAR-T collection; exchange transfusion lowers the HbS fraction in sickle cell stroke and severe acute chest syndrome.
Match coagulation products to the hole: factor replacement, vitamin K, cryoprecipitate for fibrinogen, FFP for multiple factors, and antifibrinolytics for mucosal bleeding; combining emicizumab with aPCC raises thrombosis concern.
Last updated: August 2026
This section is CPHON Domain III.A.4, III.A.7, and III.B.4: which product, for which child, and why it is modified . Technique—consent, dual identifiers, 15-minute vital signs, tubing, and rate—lives in the later supportive-care blood-product administration chapter. Do not turn this page into a skills checklist. Turn it into product choice.
Modified cellular products for immunocompromised children
Children receiving intensive chemotherapy, HSCT, or with severe T-cell immunodeficiency need irradiated cellular products. Irradiation prevents transfusion-associated graft-versus-host disease (TA-GVHD) , in which donor lymphocytes engraft and attack the recipient. TA-GVHD is usually fatal. Directing a unit of unirradiated packed red cells to a child on day +4 after allogeneic transplant is a never-event. Directed donations from blood relatives are particularly risky without irradiation because of shared HLA haplotypes.
Leukoreduction removes white cells, cutting febrile non-hemolytic reactions and lowering CMV transmission and HLA alloimmunization. CMV-safe products (leukoreduced and/or CMV-seronegative per blood-bank policy) are used for CMV-seronegative immunocompromised children, including HSCT recipients and some infants. Follow the blood bank's operational definition; the CPHON concept is CMV-safe for the immunocompromised , not a homemade serology algorithm.
A 2-year-old with AML on induction who needs red cells gets irradiated, leukoreduced (and CMV-safe per policy) product. "Any O-negative unit from the trauma fridge" is not a pediatric oncology plan.
Platelets, red cells, and refractoriness—thresholds are protocol-specific
Platelets are given for active bleeding or to cover a procedure (lumbar puncture, central-line placement, surgery) at a count the protocol or surgeon names. Red cells are given for symptomatic anemia —tachycardia, hypoxia, high-output strain, severe pallor with distress—not because a number is aesthetically low. Do not invent a universal 7 g/dL red-cell trigger as ONCC fact. Cooperative groups and transplant programs publish their own numbers; your job is the indication (bleeding, procedure, symptoms) and the modified product, not a single national gram-per-deciliter law.
Platelet refractoriness means the count does not rise as expected after transfusion. Immune causes involve HLA or platelet-specific antibodies. Next products are HLA-matched or crossmatched platelets , plus investigation of fever, splenomegaly, and consumption. Keep giving random pools forever while the child oozes is not a strategy.
A 6-year-old with ALL and platelets of 8,000/µL who needs an intrathecal dose gets platelets timed to the lumbar puncture per protocol. A well-appearing outpatient with a hemoglobin of 8.4 g/dL and no symptoms is not automatically transfused because a website said "seven."
Reactions: stop the transfusion
When a reaction is suspected, stop the transfusion , keep the line open with saline, check the identity of child and unit, notify the provider and blood bank, and treat by syndrome. Do not finish the bag "because there are only 40 mL left."
Reaction Bedside clues Immediate concept
Allergic / anaphylactic Urticaria, wheeze, hypotension Stop; antihistamine for isolated hives per protocol; epinephrine for anaphylaxis
Febrile non-hemolytic Fever, chills, no hemolysis Stop and evaluate; leukoreduced products reduce risk
Acute hemolytic Fever, flank or back pain, hemoglobinuria, shock (ABO mismatch) Stop; fluids; treat as a clerical emergency
TRALI Acute hypoxemia and non-cardiogenic pulmonary edema during or shortly after transfusion Stop; oxygen and ventilatory support; not simple volume overload
TACO Respiratory distress with hypertension, raised JVP, response to diuretic—volume overload Stop; sit up; diuretic per order; distinguish from TRALI
TRALI (transfusion-related acute lung injury) versus TACO (transfusion-associated circulatory overload) is the discrimination item: TRALI is permeability edema, often hypotensive or febrile; TACO is hydrostatic overload, often hypertensive. Both start with stop .
A 5-year-old who wheezes and drops blood pressure three minutes into platelets has anaphylaxis until proven otherwise: stop, epinephrine per emergency protocol, and do not restart the same unit. A 16-year-old on chronic transfusion who becomes hypoxic and hypertensive with rales near the end of a second red-cell unit is TACO until you prove TRALI; sit the child up and give the ordered diuretic after the bag is stopped.
Leukapheresis, exchange transfusion, and coagulation products
Leukapheresis mechanically removes circulating blasts in hyperleukocytosis when the team chooses it, and it is also how CAR-T T cells are collected. Hyperleukocytosis emergency management—hydration, avoidance of empiric red-cell transfusion that raises viscosity, uric-acid control—lives in the later emergency hyperleukocytosis chapter . Here, know that leukapheresis is a treatment modality with two pediatric jobs: selected hyperleukocytosis and cellular-therapy collection. A 15-year-old with AML, a white-cell count in the hundreds of thousands, and respiratory distress is an emergency-chapter patient who may also be on an apheresis machine; an 8-year-old in remission walking to leukapheresis for CAR-T collection is a planned collection.
Exchange transfusion in sickle cell disease replaces sickle red cells with hemoglobin-A cells and lowers the HbS fraction without overshooting viscosity the way a simple large-volume transfusion can. Classic indications include overt ischemic stroke and severe acute chest syndrome . Chronic exchange or simple-transfusion programs prevent recurrent stroke after abnormal transcranial Doppler—see the sickle-cell section. Technique of the exchange belongs with administration; the CPHON product choice here is exchange rather than simple transfusion when viscosity and HbS fraction are the problem.
Coagulation therapy matches the missing protein or the clot-stability problem:
Factor replacement (VIII for hemophilia A, IX for B) for bleeds and procedures.
Vitamin K for deficiency or warfarin-type coagulopathy (dietary, malabsorption, some antibiotics).
Cryoprecipitate when fibrinogen is the hole (DIC, massive bleed, congenital hypofibrinogenemia).
Fresh frozen plasma (FFP) for multiple-factor replacement or coagulopathy when a specific concentrate is not the right product.
Antifibrinolytics — aminocaproic acid or tranexamic acid —for mucosal bleeding (mouth, nose, menses) as adjuncts, not as substitutes for factor in a head bleed.
Emicizumab is a factor VIII mimetic for hemophilia A prophylaxis. Combining it with activated prothrombin complex concentrate (aPCC) raises thrombosis and thrombotic microangiopathy risk—caution, call the hemophilia center, do not stack those products as a default (see the coagulopathy section).
A 10-year-old with hemophilia A and persistent epistaxis may receive factor plus an antifibrinolytic. A 4-year-old on emicizumab whose knee is swollen still needs a breakthrough factor plan, not an aPCC-plus-emicizumab stack. A toddler with DIC and an unmeasurable fibrinogen needs cryoprecipitate in the conversation, not FFP alone as a fibrinogen strategy.
The CPHON product on this page is the right modified unit, the right reason to transfuse, a stopped bag when a reaction starts, leukapheresis and exchange named for their indications, and coagulation products matched to fibrinogen, vitamin K, mucosa, or factor—not a universal hemoglobin of 7.